Uncategorized

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

|

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.  More than 75% of people treated with Gazyva plus standard therapy achieved at least … New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

|

People living with lupus can have early access to innovative therapies alongside personalized support from a broader care team. How? Through participation in clinical trials.  Historically, clinical trial participation for lupus was discussed only after standard treatments failed the patient. Now, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, is working to make … Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

Lupus Clinical Research: A New Wave of Innovation 

|

A wave of lupus clinical research advances has been building over the past decade.  Now, it is reaching a crest.  A 2025 pipeline report identifies over 140 lupus therapies from 120+ companies now in clinical trials.i This surge of innovation is translating into potential treatments that are targeted, safer, and showing potential effectiveness for people living with lupus—offering more choices and options for treating the disease.  “This is … Lupus Clinical Research: A New Wave of Innovation 

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative

|
Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative.

Imagine a future where everyday choices – like what people eat – could shape how lupus is treated and managed. That future may be closer than ever.   Earlier this year, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, launched a pioneering initiative: Investigate Dietary Approaches for Lupus (IDEAL). It is the first-ever program … Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative

An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

|
Can diet make a difference in lupus?

Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of a groundbreaking initiative by Lupus Therapeutics (LT), the clinical research affiliate of the Lupus Research Alliance (LRA), called IDEAL (Investigate Dietary Approaches for Lupus). IDEAL will provide up to two grants for pilot clinical studies evaluating … An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

|
Breaking News

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the … Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP  Expresses Optimism About the Current State of Lupus Research

|

Today is “Endpoints Clinical Trials Day,” hosted by international biopharma news outlet Endpoints News. The day features a series of discussions on the latest trends in clinical trials in the US and abroad, the regulatory environment, and how industry and others are helping to improve trial strategies of the future. These include plans to ensure … On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP  Expresses Optimism About the Current State of Lupus Research

LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

|

New ACR guidelines for advancing the management of lupus nephritis (LN). Novel approaches and promising data from early- to late-stage lupus treatments in development, including CAR T cell therapies. Strategies for promoting equity in lupus clinical trials. These were among the key presentations at ACR (American College of Rheumatology) Convergence 2024. Lupus Therapeutics (LT), the … LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

|
News from ACR Convergence 2024

The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the Lupus … ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

|

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in … Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial